Abstract
Purpose of Review
In-stent restenosis (ISR) is a complex disease process that became apparent shortly after the introduction of stents into clinical practice. This review seeks to define in-stent restenosis (ISR) as well as to summarize the major treatment options that have been developed and studied over the past two decades.
Recent Findings
Recent developments in drug-coated balloons and bioresorbable vascular scaffolds have added new potential treatments for ISR. Two recent network meta-analyses performed a head-to-head comparison of all the various treatment modalities in order to identify the best approach to management of ISR.
Summary
Current data suggests that repeat stenting with second-generation drug-eluting stents is most likely to lead to the best angiographic and clinical outcomes. In situations where repeat stenting is not preferable, drug-coated balloon therapy seems to be a reasonably effective alternative.
Similar content being viewed by others
References
Papers of particular interest, published recently, have been highlighted as: •• Of major importance
Mukherjee, et al. Optimal treatment for in-stent restenosis after BMS—DES, coated balloon, or scalpel? Eur Heart J. 2008;29(Issue 13):1595–6. https://doi.org/10.1093/eurheartj/ehn068.
Mehran R, Dangas G, Abizaid AS, Mintz GS, Lansky AJ, Satler LF, et al. Angiographic patterns of in-stent restenosis: classification and implications for long-term outcome. Circulation. 1999;100(18):1872–8. https://doi.org/10.1161/01.CIR.100.18.1872.
Kuntz RE, Baim DS. Defining coronary restenosis. Newer clinical and angiographic paradigms. Circulation. 1993;88(3):1310–23. https://doi.org/10.1161/01.CIR.88.3.1310.
Cassese S, Byrne RA, Tada T, Pinieck S, Joner M, Ibrahim T, et al. Incidence and predictors of restenosis after coronary stenting in 10 004 patients with surveillance angiography. Heart. 2013;100(2):153–9. https://doi.org/10.1136/heartjnl-2013-304933.
Byrne RA, Joner M, Tada T, Kastrati A. Restenosis in bare metal and drug-eluting stents: distinct mechanistic insights from histopathology and optical intravascular imaging. Minerva Cardioangiol. 2012;60(5):473–89.
Nakazawa G, Otsuka F, Nakano M, Vorpahl M, Yazdani SK, Ladich E, et al. The pathology of neoatherosclerosis in human coronary implants bare-metal and drug-eluting stents. J Am Coll Cardiol. 2011;57(11):1314–22. https://doi.org/10.1016/j.jacc.2011.01.011.
Fujii K, Mintz GS, Kobayashi Y, Carlier SG, Takebayashi H, Yasuda T, et al. Contribution of stent underexpansion to recurrence after sirolimus-eluting stent implantation for in-stent restenosis. Circulation. 2004;109(9):1085–8. https://doi.org/10.1161/01.CIR.0000121327.67756.19.
Angiolillo DJ, Sabatá M, Alfonso F, Macaya C. “Candy wrapper” effect after drug-eluting stent implantation: déjà vu or stumbling over the same stone again? Catheter Cardiovasc Interv. 2004;61(3):387–91. https://doi.org/10.1002/ccd.10765.
Dangas GD, Claessen BE, Caixeta A, Sanidas EA, Mintz GS, Mehran R. In-stent restenosis in the drug-eluting stent era. J Am Coll Cardiol. 2010;56(23):1897–907. https://doi.org/10.1016/j.jacc.2010.07.028.
Kang S, Mintz GS, Akasaka T, Park D, Lee J, Kim W, et al. Optical coherence tomographic analysis of in-stent neoatherosclerosis after drug-eluting stent implantation. Circulation. 2011;123(25):2954–63. https://doi.org/10.1161/CIRCULATIONAHA.110.988436.
Chen MS, John JM, Chew DP, Lee DS, Ellis SG, Bhatt DL. Bare metal stent restenosis is not a benign clinical entity. Am Heart J. 2006;151(6):1260–4. https://doi.org/10.1016/j.ahj.2005.08.011.
Uchida T, Popma J, Stone GW, Ellis SG, Turco MA, Ormiston JA, et al. The clinical impact of routine angiographic follow-up in randomized trials of drug-eluting stents: a critical assessment of “oculostenotic” reintervention in patients with intermediate lesions. JACC Cardiovasc Interv. 2010;3(4):403–11. https://doi.org/10.1016/j.jcin.2010.01.010.
Lopez-Palop R, Pinar E, Lozano I, Saura D, Picó F, Valdés M. Utility of the fractional flow reserve in the evaluation of angiographically moderate in-stent restenosis. Eur Heart J. 2004;25(22):2040–7. https://doi.org/10.1016/j.ehj.2004.07.016.
Nam C, Rha S, Koo B, Doh J, Chung W, Yoon M, et al. Usefulness of coronary pressure measurement for functional evaluation of drug-eluting stent restenosis. Am J Cardiol. 2011;107(12):1783–6. https://doi.org/10.1016/j.amjcard.2011.02.328.
Eraser Investigators. Acute platelet inhibition with abciximab does not reduce in-stent restenosis (ERASER study). Circulation. 1999;100(8):799–806.
Hausleiter J, Kastrati A, Mehilli J, Vogeser M, Zohlnhöfer D, Schühlen H, et al. Randomized, double-blind, placebo-controlled trial of oral sirolimus for restenosis prevention in patients with in-stent restenosis: the Oral Sirolimus to Inhibit Recurrent In-stent Stenosis (OSIRIS) trial. Circulation. 2004;110(7):790–5. https://doi.org/10.1161/01.CIR.0000138935.17503.35.
Kufner S, Hausleiter J, Ndrepepa G, Schulz S, Bruskina O, Byrne RA, et al. Long-term risk of adverse outcomes and new malignancies in patients treated with oral sirolimus for prevention of restenosis. JACC Cardiovasc Interv. 2009;2(11):1142–8. https://doi.org/10.1016/j.jcin.2009.08.015.
Alfonso F, Pérez-Vizcayno MJ, Hernández R, Goicolea J, Fernández-Orίtz A, Escaned J, et al. Long-term outcome and determinants of event-free survival in patients treated with balloon angioplasty for in-stent restenosis. Am J Cardiol. 1999;83(8):1268–70. https://doi.org/10.1016/S0002-9149(99)00071-5.
Mehran R, Mintz GS, Popma JJ, Pichard AD, Satler LF, Kent KM, et al. Mechanisms and results of balloon angioplasty for the treatment of in-stent restenosis. Am J Cardiol. 1996;78(6):618–22. https://doi.org/10.1016/S0002-9149(96)00381-5.
•• Alfonso F, Byrne RA, Rivero F, Kastrati A. Current treatment of in-stent restenosis. J Am Coll Cardiol. 2014;63(24):2659–73. https://doi.org/10.1016/j.jacc.2014.02.545. This study provides available clinical data for different therapeutic modalities for in-stent restenosis.
Alfonso F, García P, Fleites H, Pimentel G, Sabaté M, Hernández R, et al. Repeat stenting for the prevention of the early lumen loss phenomenon in patients with in-stent restenosis. Am Heart J. 2005;149(2):e8.
Waksman R, White RL, Chan RC, Bass BG, Geirlach L, Mintz GS, et al. Intracoronary gamma-radiation therapy after angioplasty inhibits recurrence in patients with in-stent restenosis. Circulation. 2000;101(18):2165–71. https://doi.org/10.1161/01.CIR.101.18.2165.
Leon MB, Teirstein PS, Moses JW, Tripuraneni P, Lansky AJ, Jani S, et al. Localized intracoronary gamma-radiation therapy to inhibit the recurrence of restenosis after stenting. N Engl J Med. 2001;344(4):250–6. https://doi.org/10.1056/NEJM200101253440402.
Holmes DR, Teirstein P, Satler L, Sketch M, O'Malley J, Popma JJ, et al. Sirolimus-eluting stents vs vascular brachytherapy for in-stent restenosis within bare-metal stents: the SISR randomized trial. JAMA. 2006;295(11):1264–73. https://doi.org/10.1001/jama.295.11.1264.
Stone GW, Ellis SG, O'Shaughnessy CD, Martin SL, Satler L, McGarry T, et al. Paclitaxel-eluting stents vs vascular brachytherapy for in-stent restenosis within bare-metal stents: the TAXUS V ISR randomized trial. JAMA. 2006;295(11):1253–63. https://doi.org/10.1001/jama.295.11.1253.
Montorsi P, Galli S, Fabbiocchi F, Trabattoni D, Ravagnani PM, Bartorelli AL. Randomized trial of conventional balloon angioplasty versus cutting balloon for in-stent restenosis. Acute and 24-hour angiographic and intravascular ultrasound changes and long-term follow-up. Ital Heart J. 2004;5(4):271–9.
Adamian M, Colombo A, Briguori C, Nishida T, Marsico F, Di Mario C, et al. Cutting balloon angioplasty for the treatment of in-stent restenosis: a matched comparison with rotational atherectomy, additional stent implantation and balloon angioplasty. J Am Coll Cardiol. 2001;38(3):672–9. https://doi.org/10.1016/S0735-1097(01)01458-9.
Albiero R, Silber S, Di Mario C, Cernigliaro C, Battaglia S, Reimers B, et al. Cutting balloon versus conventional balloon angioplasty for the treatment of in-stent restenosis: results of the restenosis cutting balloon evaluation trial (RESCUT). J Am Coll Cardiol. 2004;43(6):943–9. https://doi.org/10.1016/j.jacc.2003.09.054.
Kufner S, Joner M, Schneider S, Tölg R, Zrenner B, Repp J, et al. Neointimal modification with scoring balloon and efficacy of drug-coated balloon therapy in patients with restenosis in drug-eluting coronary stents. J Am Coll Cardiol Intv. 2017;10(13):1332–40. https://doi.org/10.1016/j.jcin.2017.04.024.
Mintz GS, Hoffmann R, Mehran R, Pichard AD, Kent KM, Satler LF, et al. In-stent restenosis: the Washington hospital center experience. Am J Cardiol. 1998;81(7):13E.
Mehran R, Dangas G, Mintz GS, Waksman R, Abizaid A, Satler LF, et al. Treatment of in-stent restenosis with excimer laser coronary angioplasty versus rotational atherectomy: comparative mechanisms and results. Circulation. 2000;101(21):2484–9. https://doi.org/10.1161/01.CIR.101.21.2484.
Sharma SK, Kini A, Mehran R, Lansky A, Kobayashi Y, Marmur JD. Randomized trial of rotational Atherectomy versus balloon angioplasty for diffuse in-stent restenosis (ROSTER). Am Heart J. 2004;147(1):16–22. https://doi.org/10.1016/j.ahj.2003.07.002.
vom Dahl J, Dietz U, Haager PK, Silber S, Niccoli L, Buettner HJ, et al. Rotational atherectomy does not reduce recurrent in-stent restenosis. Circulation. 2002;105(5):583–8. https://doi.org/10.1161/hc0502.103347.
Macaya C, Serruys PW, Ruygrok P, Suryapranata H, Mast G, Klugmann S, et al. Continued benefit of coronary stenting versus balloon angioplasty: one-year clinical follow-up of Benestent trial. J Am Coll Cardiol. 1996;27(2):255–61. https://doi.org/10.1016/0735-1097(95)00473-4.
•• Stefanini GG, Holmes DR. Drug-eluting coronary-artery stents. N Engl J Med. 2013;368(3):254–65. https://doi.org/10.1056/NEJMra1210816. This review provides the currently available drug-eluting stents and their indications with evidence from randomized control trials.
Kastrati A, Mehilli J, von Beckerath N, Dibra A, Hausleiter J, Pache J, et al. Sirolimus-eluting stent or paclitaxel-eluting stent vs balloon angioplasty for prevention of recurrences in patients with coronary in-stent restenosis: a randomized controlled trial. JAMA. 2005;293(2):165–71. https://doi.org/10.1001/jama.293.2.165.
Alfonso F, Pérez-Vizcayno M, Hernandez R, Bethencourt A, Martí V, López-Mínguez JR, et al. A randomized comparison of sirolimus-eluting stent with balloon angioplasty in patients with in-stent restenosis: results of the restenosis Intrastent: balloon angioplasty versus elective Sirolimus-eluting stenting (RIBS-II) trial. J Am Coll Cardiol. 2006;47(11):2152–60. https://doi.org/10.1016/j.jacc.2005.10.078.
Alfonso F, Pérez-Vizcayno M, Hernández R, Bethencourt A, Martí V, López-Mínguez JR, et al. Long-term clinical benefit of sirolimus-eluting stents in patients with in-stent restenosis results of the RIBS-II (restenosis intra-stent: balloon angioplasty vs. elective sirolimus-eluting stenting) study. J Am Coll Cardiol. 2008;52(20):1621–7. https://doi.org/10.1016/j.jacc.2008.08.025.
Byrne RA, Cassese S, Windisch T, King LA, Joner M, Tada T, et al. Differential relative efficacy between drug-eluting stents in patients with bare metal and drug-eluting stent restenosis; evidence in support of drug resistance: insights from the ISAR-DESIRE and ISAR-DESIRE 2 trials. EuroIntervention. 2013;9(7):797–802. https://doi.org/10.4244/EIJV9I7A132.
Latib A, Mussardo M, Ielasi A, Tarsia G, Godino C, Al-Lamee R, et al. Long-term outcomes after the percutaneous treatment of drug-eluting stent restenosis. J Am Coll Cardiol Intv. 2011;4(2):155–64. https://doi.org/10.1016/j.jcin.2010.09.027.
Alfonso F, Pérez-Vizcayno MJ, Dutary J, Zueco J, Cequier A, García-Touchard A, et al. Implantation of a drug-eluting stent with a different drug (switch strategy) in patients with drug-eluting stent restenosis. Results from a prospective multicenter study (RIBS III [restenosis intra-stent: balloon angioplasty versus drug-eluting stent]). JACC Cardiovasc Interv. 2012;5(7):728–37. https://doi.org/10.1016/j.jcin.2012.03.017.
Scheller B, Hehrlein C, Bocksch W, Rutsch W, Haghi D, Dietz U, et al. Treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter. N Engl J Med. 2006;355(20):2113–24. https://doi.org/10.1056/NEJMoa061254.
Unverdorben M, Vallbracht C, Cremers B, Heuer H, Hengstenberg C, Maikowski C, et al. Paclitaxel-coated balloon catheter versus paclitaxel-coated stent for the treatment of coronary in-stent restenosis. Circulation. 2009;119(23):2986–94. https://doi.org/10.1161/CIRCULATIONAHA.108.839282.
Alfonso F, Pérez-Vizcayno MJ, Cárdenas A, del Blanco BG, Seidelberger B, Iñiguez A, et al. A randomized comparison of drug-eluting balloon versus everolimus-eluting stent in patients with bare-metal stent–in-stent restenosis: the RIBS V clinical trial (restenosis intra-stent of bare metal stents: paclitaxel-eluting balloon vs. everolimus-eluting stent). J Am Coll Cardiol. 2014;63(14):1378–86.
Habara S, Iwabuchi M, Inoue N, Nakamura S, Asano R, Nanto S, et al. A multicenter randomized comparison of paclitaxel-coated balloon catheter with conventional balloon angioplasty in patients with bare-metal stent restenosis and drug-eluting stent restenosis. Am Heart J. 2013;166(3):533. e2.
Habara S, Mitsudo K, Kadota K, Goto T, Fujii S, Yamamoto H, et al. Effectiveness of paclitaxel-eluting balloon catheter in patients with sirolimus-eluting stent restenosis. J Am Coll Cardiol Intv. 2011;4(2):149–54. https://doi.org/10.1016/j.jcin.2010.10.012.
Byrne RA, Neumann F, Mehilli J, Pinieck S, Wolff B, Tiroch K, et al. Paclitaxel-eluting balloons, paclitaxel-eluting stents, and balloon angioplasty in patients with restenosis after implantation of a drug-eluting stent (ISAR-DESIRE 3): a randomised, open-label trial. Lancet. 2013;381(9865):461–7. https://doi.org/10.1016/S0140-6736(12)61964-3.
Alfonso F, Pérez-Vizcayno MJ, Cárdenas A, del Blanco BG, García-Touchard A, López-Minguéz JR, et al. A prospective randomized trial of drug-eluting balloons versus everolimus-eluting stents in patients with in-stent restenosis of drug-eluting stents: the RIBS IV randomized clinical trial. J Am Coll Cardiol. 2015;66(1):23–33. https://doi.org/10.1016/j.jacc.2015.04.063.
Jamshidi P, Nyffenegger T, Sabti Z, Buset E, Toggweiler S, Kobza R, et al. A novel approach to treat in-stent restenosis: 6- and 12-month results using the everolimus-eluting bioresorbable vascular scaffold. EuroIntervention. 2016;11(13):1479–86. https://doi.org/10.4244/EIJV11I13A287.
Rivero F, Bastante T, Cuesta J, Benedicto A, Restrepo JA, Alfonso F. Treatment of in-stent restenosis with bioresorbable vascular scaffolds: optical coherence tomography insights. Can J Cardiol. 2015;31(3):255–9. https://doi.org/10.1016/j.cjca.2014.11.017.
Alfonso F, Pérez-Vizcayno MJ, Gómez-Recio M, Insa L, Calvo I, Hernández JM, et al. Implications of the “watermelon seeding” phenomenon during coronary interventions for in-stent restenosis. Catheter Cardiovasc Interv. 2005;66(4):521–7. https://doi.org/10.1002/ccd.20524.
Alfonso F, Zueco J, Cequier A, Mantilla R, Bethencourt A, López-Minguez JR, et al. A randomized comparison of repeat stenting with balloon angioplasty in patients with in-stent restenosis. J Am Coll Cardiol. 2003;42(5):796–805. https://doi.org/10.1016/S0735-1097(03)00852-0.
Alfonso F, Melgares R, Mainar V, Lezaún R, Vázquez N, Tascón J, et al. Therapeutic implications of in-stent restenosis located at the stent edge. Insights from the restenosis intra-stent balloon angioplasty versus elective stenting (RIBS) randomized trial. Eur Heart J. 2004;25(20):1829–35. https://doi.org/10.1016/j.ehj.2004.07.019.
Siontis GCM, Stefanini GG, Mavridis D, Siontis KC, Alfonso F, Pérez-Vizcayno MJ, et al. Percutaneous coronary interventional strategies for treatment of in-stent restenosis: a network meta-analysis. Lancet. 2015;386(9994):655–64. https://doi.org/10.1016/S0140-6736(15)60657-2.
Giacoppo D, Gargiulo G, Aruta P, Capranzano P, Tamburino C, Capodanno D. Treatment strategies for coronary in-stent restenosis: systematic review and hierarchical Bayesian network meta-analysis of 24 randomised trials and 4880 patients. BMJ. 2015;351:h5392.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of Interest
Charles Nicolais, Vladimir Lakhter, Hafeez Ul Hassan Virk, Partha Sardar, Chirag Bavishi, Brian O’Murchu, and Saurav Chatterjee declare that they have no conflict of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Additional information
This article is part of the Topical Collection on Ischemic Heart Disease
Rights and permissions
About this article
Cite this article
Nicolais, C., Lakhter, V., Virk, H.U.H. et al. Therapeutic Options for In-Stent Restenosis. Curr Cardiol Rep 20, 7 (2018). https://doi.org/10.1007/s11886-018-0952-4
Published:
DOI: https://doi.org/10.1007/s11886-018-0952-4